ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM
Abstract Number: 2716
A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis
Systemic Sclerosis and Related Disorders – Clinical Poster III
9:00AM-11:00AM
Abstract Number: 2009
A Novel Role of ZCCHC6 in the Regulation of MMP13 in Experimental Osteoarthritis in Mice
Osteoarthritis and Joint Biology – Basic Science Poster II
9:00AM-11:00AM
Abstract Number: 2342
A Pan-Canadian Study of Factors Associated with Perceived Doctor-Patient Communication in Patients with Systemic Lupus Erythematosus
Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives
9:00AM-11:00AM
Abstract Number: 2510
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds
9:00AM-11:00AM
Abstract Number: 2738
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vasculitis – ANCA-Associated Poster II
9:00AM-11:00AM
Abstract Number: 2521
A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds
9:00AM-11:00AM
Abstract Number: 1989
A Regulatory Role of ANTXR1 in RANKL-Induced Osteoclast Differentiation and Function
Osteoarthritis and Joint Biology – Basic Science Poster II
9:00AM-11:00AM
Abstract Number: 2127
A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2769
A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 2039
A Survey of Blood and Synovial Tissue Myeloid Cells in RA Patients By Transcriptional Profiling
Rheumatoid Arthritis – Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2677
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Poster III: Treatment
9:00AM-11:00AM
Abstract Number: 2228
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II
9:00AM-11:00AM
Abstract Number: 2308
Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Network Meta-Analysis
Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 2554
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment
9:00AM-11:00AM
Abstract Number: 2064
Aberrant Distribution and Function of Plasmacytoid Dendritic Cells in Patients with Ankylosing Spondylitis Are Associated with Unfolded Protein Response
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology